No excess mortality risk for 10-­years survivors after high dose therapy with autologous stem cell transplantation (HDT‐ASCT) for relapsed/refractory Hodgkin's lymphoma (HL)

Details

Language :

English

Database :

OpenAIRE

Accession number :

edsair.doi...........33779e30503e0910ee8b096313efb367

Full Text :

https://doi.org/10.13140/2.1.1727.8723